Search Results - "Motyl, Mary"

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial by Maertens, Johan A, Rahav, Galia, Lee, Dong-Gun, Ponce-de-León, Alfredo, Ramírez Sánchez, Isabel Cristina, Klimko, Nikolay, Sonet, Anne, Haider, Shariq, Diego Vélez, Juan, Raad, Issam, Koh, Liang-Piu, Karthaus, Meinolf, Zhou, Jianying, Ben-Ami, Ronen, Motyl, Mary R, Han, Seongah, Grandhi, Anjana, Waskin, Hetty

“…Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have…”
Get full text

Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene by Matsumura, Yasufumi, Pitout, Johann D D, Gomi, Ryota, Matsuda, Tomonari, Noguchi, Taro, Yamamoto, Masaki, Peirano, Gisele, DeVinney, Rebekah, Bradford, Patricia A, Motyl, Mary R, Tanaka, Michio, Nagao, Miki, Takakura, Shunji, Ichiyama, Satoshi

“…The Escherichia coli sequence type (ST) 131 C2/H30Rx clade with the blaCTX-M-15 gene had been most responsible for the global dissemination of…”
Get full text

In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes—Study for Monitoring Antimicrobial Resistance Trends, United States 2015–2017 by Karlowsky, James A, Lob, Sibylle H, Raddatz, Janet, DePestel, Daryl D, Young, Katherine, Motyl, Mary R, Sahm, Daniel F

“…Abstract Background Multidrug-resistant (MDR) bacteria are frequently defined using the criteria established by Magiorakos et al [Clin Microbiol Infect…”
Get full text

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program) by Lob, Sibylle H, Hackel, Meredith A, Kazmierczak, Krystyna M, Young, Katherine, Motyl, Mary R, Karlowsky, James A, Sahm, Daniel F

“…Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including carbapenemase (KPC), and is currently in clinical development in…”
Get full text

Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates by JIMENEZ-ORTIGOSA, Cristina, PADERU, Padmaja, MOTYL, Mary R, PERLIN, David S

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014 by Karlowsky, James A, Lob, Sibylle H, Kazmierczak, Krystyna M, Badal, Robert E, Young, Katherine, Motyl, Mary R, Sahm, Daniel F

“…The Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program collected 103,960 isolates of from 2008 to 2014. From this isolate…”
Get full text

Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014 by Peirano, Gisele, Matsumura, Yasufumi, Adams, Mark D, Bradford, Patricia, Motyl, Mary, Chen, Liang, Kreiswirth, Barry N, Pitout, Johann D D

“…We performed whole-genome sequencing on 170 clinical carbapenemase-producing Enterobacter spp. isolates collected globally during 2008-2014. The most common…”
Get full text

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa by Young, Katherine, Painter, Ronald E, Raghoobar, Susan L, Hairston, Nichelle N, Racine, Fred, Wisniewski, Douglas, Balibar, Carl J, Villafania, Artjohn, Zhang, Rumin, Sahm, Daniel F, Blizzard, Timothy, Murgolo, Nicholas, Hammond, Milton L, Motyl, Mary R

“…The prevalence of antibiotic resistance is increasing, and multidrug-resistant Pseudomonas aeruginosa has been identified as a serious threat to human health…”
Get full text

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019 by Karlowsky, James A, Lob, Sibylle H, Young, Katherine, Motyl, Mary R, Sahm, Daniel F

“…Ceftolozane/tazobactam (C/T) is approved in 70 countries, including the United States, for the treatment of patients with hospital-acquired and…”
Get full text

Global Molecular Epidemiology of IMP-Producing Enterobacteriaceae by Matsumura, Yasufumi, Peirano, Gisele, Motyl, Mary R, Adams, Mark D, Chen, Liang, Kreiswirth, Barry, DeVinney, Rebekah, Pitout, Johann D D

“…International data on the molecular epidemiology of with IMP carbapenemases are lacking. We performed short-read (Illumina) whole-genome sequencing on a global…”
Get full text

In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017 by Lob, Sibylle H, Karlowsky, James A, Young, Katherine, Motyl, Mary R, Hawser, Stephen, Kothari, Nimmi D, Sahm, Daniel F

“…Infections attributable to carbapenem-resistant Gram-negative bacilli are increasing globally. New antimicrobial agents are urgently needed to treat patients…”
Get full text

Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019 by Karlowsky, James A., Lob, Sibylle H., DeRyke, C. Andrew, Siddiqui, Fakhar, Young, Katherine, Motyl, Mary R., Sahm, Daniel F.

“…This study aimed to determine the prevalence of extended-spectrum β-lactamase (ESBL) non-carbapenem-resistant Enterobacterales (non-CRE) phenotype among…”
Get full text

In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria by Hirsch, Elizabeth B, Ledesma, Kimberly R, Chang, Kai-Tai, Schwartz, Michael S, Motyl, Mary R, Tam, Vincent H

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Genomic epidemiology of global VIM-producing Enterobacteriaceae by Matsumura, Yasufumi, Peirano, Gisele, Devinney, Rebekah, Bradford, Patricia A, Motyl, Mary R, Adams, Mark D, Chen, Liang, Kreiswirth, Barry, Pitout, Johann D D

“…International data on the molecular epidemiology of Enterobacteriaceae with VIM carbapenemases are limited. We performed short read (Illumina) WGS on a global…”
Get full text

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme by Karlowsky, James A, Lob, Sibylle H, Kazmierczak, Krystyna M, Hawser, Stephen P, Magnet, Sophie, Young, Katherine, Motyl, Mary R, Sahm, Daniel F

“…Abstract Objectives Relebactam is an inhibitor of class A β-lactamases, including KPC β-lactamases, and class C β-lactamases, and is currently under clinical…”
Get full text

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17 by Lob, Sibylle H, Karlowsky, James A, Young, Katherine, Motyl, Mary R, Hawser, Stephen, Kothari, Nimmi D, Gueny, Melinda E, Sahm, Daniel F

“…Relebactam is a diazabicyclooctane non-β-lactam inhibitor of Ambler class A and C β-lactamases that is in clinical development in combination with…”
Get full text

In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods by PFALLER, Michael A, MESSER, Shawn A, MOTYL, Mary R, JONES, Ronald N, CASTANHEIRA, Mariana

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020 by Karlowsky, James A, Lob, Sibylle H, DeRyke, C Andrew, Hilbert, David W, Wong, Michael T, Young, Katherine, Siddiqui, Fakhar, Motyl, Mary R, Sahm, Daniel F

“…Ceftolozane-tazobactam (C/T), imipenem-relebactam (IMR), and ceftazidime-avibactam (CZA) were tested against 2,531 P. aeruginosa strains isolated from patients…”
Get full text

In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016) by Karlowsky, James A., Kazmierczak, Krystyna M., Young, Katherine, Motyl, Mary R., Sahm, Daniel F.

“…The Clinical and Laboratory Standards Institute (CLSI)-defined broth microdilution testing method (M07, 11th edition, 2018) was used to determine MICs for…”
Get full text

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020 by Lob, Sibylle H., Hawser, Stephen P., Siddiqui, Fakhar, Alekseeva, Irina, DeRyke, C. Andrew, Young, Katherine, Motyl, Mary R., Sahm, Daniel F.

“…Antimicrobial susceptibility was determined for clinical gram-negative isolates from Czech Republic, Hungary, and Poland, where published data for…”
Get full text